| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Yashpal Singh Malik | Q37367021 |
| Kuldeep Dhama | Q37367050 | ||
| Ashok Munjal | Q56425202 | ||
| Rekha Khandia | Q60609329 | ||
| Wanpen Chaicumpa | Q60976993 | ||
| Kumaragurubaran Karthik | Q56424998 | ||
| P2093 | author name string | Raj Kumar Singh | |
| Ruchi Tiwari | |||
| P2860 | cites work | Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse | Q21144516 |
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections | Q37793734 | ||
| Animal models of dengue virus infection | Q37987131 | ||
| Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection | Q38087545 | ||
| Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives | Q38156667 | ||
| DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. | Q38157397 | ||
| Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue | Q38157807 | ||
| Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice | Q38158000 | ||
| A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement. | Q38158037 | ||
| Zika enhancement: a reality check | Q38158442 | ||
| Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype Fab complex. | Q38158627 | ||
| Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5 | Q38237638 | ||
| Viral RNA detection by RIG-I-like receptors | Q38320905 | ||
| Neuropathogenesis of Zika Virus Infection : Potential Roles of Antibody-Mediated Pathology | Q56434705 | ||
| Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo | Q60430715 | ||
| Pathogenic mechanisms of caprine arthritis-encephalitis virus | Q45786498 | ||
| An explanation for enhanced virus plaque formation in chick embryo cells | Q45791171 | ||
| Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression | Q45881054 | ||
| High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. | Q46117208 | ||
| Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoes-Current Updates. | Q50277220 | ||
| Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection | Q21245045 | ||
| Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007 | Q22241244 | ||
| Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere | Q24261248 | ||
| Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling | Q24261402 | ||
| Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes | Q24289053 | ||
| Dengue viral protease interaction with NF-κB inhibitor α/β results in endothelial cell apoptosis and hemorrhage development | Q24299959 | ||
| In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma | Q24599396 | ||
| Antibody-dependent enhancement of Ebola virus infection | Q24683154 | ||
| Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion | Q24736978 | ||
| Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus | Q24737245 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| Zika virus – emergence, evolution, pathology, diagnosis, and control: current global scenario and future perspectives – a comprehensive review | Q24765944 | ||
| Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus | Q25161212 | ||
| Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses | Q25708015 | ||
| Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro | Q25708158 | ||
| Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus | Q26247258 | ||
| Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype | Q26252060 | ||
| Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection | Q26252507 | ||
| Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy | Q26258575 | ||
| Zika-induced antibody response enhances dengue serotype 2 replication in vitro | Q26262372 | ||
| Can non-human primates serve as models for investigating dengue disease pathogenesis? | Q26825708 | ||
| Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification | Q27315772 | ||
| How antibodies alter the cell entry pathway of dengue virus particles in macrophages | Q27334575 | ||
| Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc Receptor-Dependent and -Independent Mechanisms | Q27472823 | ||
| Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
| Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites | Q27477542 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection | Q27485051 | ||
| Role of antibodies and host cells in plaque enhancement of Murray Valley encephalitis virus | Q27486938 | ||
| A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model | Q27490166 | ||
| Viruses and autophagy | Q27491341 | ||
| Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc | Q27622123 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity | Q27860703 | ||
| THE EMERGENCE OF ARTHROPOD-BORNE VIRAL DISEASES: A GLOBAL PROSPECTIVE ON DENGUE, CHIKUNGUNYA AND ZIKA FEVERS | Q27901943 | ||
| Neutralization mechanism of a highly potent antibody against Zika virus | Q27924235 | ||
| Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection | Q28108975 | ||
| Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species | Q28119651 | ||
| Human antibody-Fc receptor interactions illuminated by crystal structures | Q28252414 | ||
| Dengue virus antibodies enhance Zika virus infection | Q28353949 | ||
| A human antibody against Zika virus crosslinks the E protein to prevent infection | Q28950443 | ||
| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity | Q29196526 | ||
| In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody | Q29619712 | ||
| Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants | Q29620637 | ||
| Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies | Q30145645 | ||
| Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico | Q30145646 | ||
| Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients | Q30392050 | ||
| First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies | Q31156754 | ||
| Autophagic machinery activated by dengue virus enhances virus replication | Q33324555 | ||
| African swine fever and classical swine fever: a review of the pathogenesis. | Q33348089 | ||
| Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles | Q33358547 | ||
| Cells in dengue virus infection in vivo. | Q33399680 | ||
| T-cell immunity to infection with dengue virus in humans | Q33414009 | ||
| Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar | Q33414901 | ||
| IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity | Q33438726 | ||
| Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection | Q33462091 | ||
| Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever | Q33481281 | ||
| Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection | Q33650118 | ||
| Hypoxia enhances antibody-dependent dengue virus infection | Q33679954 | ||
| Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region | Q38343343 | ||
| Receptors and routes of dengue virus entry into the host cells | Q38366005 | ||
| Fcγ receptor pathways during active and passive immunization | Q38615357 | ||
| Fc receptors in antibody-dependent enhancement of viral infections | Q38615396 | ||
| Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement | Q38697863 | ||
| Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions | Q38748910 | ||
| Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks | Q39038287 | ||
| Immunological enhancement of dengue virus replication. | Q39042444 | ||
| Determination of antibody concentration as the main parameter in a dengue virus antibody-dependent enhancement assay using FcγR-expressing BHK cells | Q39117650 | ||
| Low oxygen tension enhances hepatitis C virus replication. | Q39220382 | ||
| IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba | Q39372304 | ||
| Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection | Q39380603 | ||
| Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection | Q39432395 | ||
| Hypoxia blocks in vivo initiation of simian virus 40 replication at a stage preceding origin unwinding. | Q39551889 | ||
| Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies | Q39738993 | ||
| Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. | Q39795246 | ||
| Cholesterol biosynthesis modulation regulates dengue viral replication | Q39856050 | ||
| On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes | Q39876628 | ||
| Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques | Q40037808 | ||
| Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections | Q40047603 | ||
| Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice | Q40052932 | ||
| Structural Basis of Zika Virus-Specific Antibody Protection | Q40056291 | ||
| Immune enhancement of viral infection | Q40132021 | ||
| Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination | Q40140017 | ||
| Protective immune responses to dengue virus infection and vaccines: perspectives from the field to the bench | Q40166759 | ||
| Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells | Q40179370 | ||
| Antiviral action of nitric oxide on dengue virus type 2 replication | Q40233634 | ||
| Phosphorylation-independent ubiquitylation and endocytosis of Fc gammaRIIA. | Q40234447 | ||
| Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice | Q40276043 | ||
| Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection | Q40341836 | ||
| Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains | Q40377040 | ||
| Involvement of the Fc gamma receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection | Q40379127 | ||
| Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. | Q40435198 | ||
| Function of human Fc gamma RIIA and Fc gamma RIIIB. | Q40445338 | ||
| Dengue virus infects macrophages and dendritic cells in a mouse model of infection. | Q40450263 | ||
| Implications of previous subclinical dengue infection but not virus load in dengue hemorrhagic fever. | Q40470307 | ||
| Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity | Q40632182 | ||
| Chicken antibodies: taking advantage of evolution--a review | Q40866545 | ||
| Replication of dengue viruses in cultures of peripheral blood leukocytes from dengue-immune rhesus monkeys | Q40891419 | ||
| Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities | Q40933834 | ||
| Hemorrhagic fever in Thailand; recent knowledge regarding etiology | Q40951117 | ||
| Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor | Q41058944 | ||
| A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential | Q41596362 | ||
| Viral Load and Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed Zika Virus-Infected Patients | Q41920081 | ||
| Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry | Q42994502 | ||
| Downregulation of interferon-β in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6. | Q43038468 | ||
| ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS | Q44967743 | ||
| Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge | Q45324929 | ||
| In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus | Q45748716 | ||
| Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs | Q45769327 | ||
| Both viremia and cytokine levels associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese patients | Q33785818 | ||
| Delineating antibody recognition against Zika virus during natural infection | Q33798068 | ||
| Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia | Q33798508 | ||
| A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein | Q33802834 | ||
| A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus | Q33825684 | ||
| Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus | Q33850577 | ||
| Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases | Q34017276 | ||
| Regional genome transcriptional response of adult mouse brain to hypoxia | Q34046347 | ||
| Interferon-inducible effector mechanisms in cell-autonomous immunity | Q34114819 | ||
| The long elusive IgM Fc receptor, FcμR. | Q34159967 | ||
| Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication | Q34179923 | ||
| CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice | Q34289194 | ||
| Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop | Q34306877 | ||
| Autophagy facilitates antibody-enhanced dengue virus infection in human pre-basophil/mast cells. | Q34352267 | ||
| The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein | Q34386384 | ||
| Interaction sites on human IgG-Fc for FcgammaR: current models | Q34635871 | ||
| Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling | Q34649721 | ||
| Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes | Q34671059 | ||
| A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins | Q35138111 | ||
| Clinical presentations of dengue hemorrhagic fever in infants compared to children | Q35618497 | ||
| CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice | Q35760439 | ||
| Flavivirus Antagonism of Type I Interferon Signaling Reveals Prolidase as a Regulator of IFNAR1 Surface Expression | Q35861600 | ||
| The Molecular Engineering of an Anti-Idiotypic Antibody for Pharmacokinetic Analysis of a Fully Human Anti-Infective | Q35877565 | ||
| The Atg5 Atg12 conjugate associates with innate antiviral immune responses | Q35956883 | ||
| Virus infection and lipid rafts | Q36552993 | ||
| Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy | Q36628520 | ||
| Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infection | Q36654907 | ||
| A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion | Q37139005 | ||
| The cholesterol-binding antibiotic nystatin induces expression of macrophage inflammatory protein-1 in macrophages | Q37145450 | ||
| Dengue virus infection induces autophagy: an in vivo study | Q37360001 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zika virus | Q202864 |
| dengue fever | Q30953 | ||
| Dengue virus | Q476209 | ||
| antibody-dependent enhancement | Q1662341 | ||
| cross-reactivity | Q1760689 | ||
| viral antibodies | Q66021534 | ||
| Zika virus infection | Q27043680 | ||
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 597 | |
| P577 | publication date | 2018-04-23 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. | |
| P478 | volume | 9 |
| Q91656850 | A Comprehensive Review of Autophagy and Its Various Roles in Infectious, Non-Infectious, and Lifestyle Diseases: Current Knowledge and Prospects for Disease Prevention, Novel Drug Design, and Therapy |
| Q59245616 | A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates |
| Q91734951 | Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection |
| Q89659558 | Antibody-Mediated Porcine Reproductive and Respiratory Syndrome Virus Infection Downregulates the Production of Interferon-α and Tumor Necrosis Factor-α in Porcine Alveolar Macrophages via Fc Gamma Receptor I and III |
| Q84957976 | Association of past dengue fever epidemics with the risk of Zika microcephaly at the population level in Brazil |
| Q60031667 | Clinical Trials and Administration of Zika Virus Vaccine in Pregnant Women: Lessons (that Should Have Been) Learned from Excluding Immunization with the Ebola Vaccine during Pregnancy and Lactation |
| Q58795098 | Comparative Transcriptomic Analysis of Immune-Related Gene Expression in Duck Embryo Fibroblasts Following Duck Tembusu Virus Infection |
| Q61795524 | Control of Acute Arboviral Infection by Natural Killer Cells |
| Q96163477 | Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective |
| Q98770744 | Development of vaccines for SARS-CoV-2 |
| Q98578994 | Enhanced effect of modified Zika virus E antigen on the immunogenicity of DNA vaccine |
| Q92077312 | Genetic and antigenic diversity of African swine fever virus |
| Q98224836 | High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects |
| Q64259781 | Mouse Models of Heterologous Flavivirus Immunity: A Role for Cross-Reactive T Cells |
| Q96762059 | Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19 |
| Q99624588 | Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| Q63246477 | Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells |
| Q98730822 | Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development |
| Q92150862 | Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection |
| Q90339909 | Zika virus enhances monocyte adhesion and transmigration favoring viral dissemination to neural cells |
| Q57092164 | Zika virus: epidemiology, clinical aspects, diagnosis, and control of infection |
Search more.